Merck & Co., Inc. (NYSE:MRK) Holdings Lifted by Sandy Cove Advisors LLC

Sandy Cove Advisors LLC increased its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 20.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,704 shares of the company’s stock after acquiring an additional 455 shares during the period. Sandy Cove Advisors LLC’s holdings in Merck & Co., Inc. were worth $269,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of MRK. Franklin Resources Inc. lifted its position in shares of Merck & Co., Inc. by 12.9% in the third quarter. Franklin Resources Inc. now owns 16,049,161 shares of the company’s stock worth $1,759,800,000 after purchasing an additional 1,836,505 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Merck & Co., Inc. by 16.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 63,101 shares of the company’s stock valued at $7,211,000 after buying an additional 8,985 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Merck & Co., Inc. by 2.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 18,807,293 shares of the company’s stock worth $2,135,785,000 after buying an additional 514,060 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Merck & Co., Inc. by 3.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,837,354 shares of the company’s stock valued at $208,649,000 after acquiring an additional 62,047 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of Merck & Co., Inc. by 3.3% in the third quarter. Captrust Financial Advisors now owns 1,102,540 shares of the company’s stock worth $125,204,000 after acquiring an additional 34,715 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $98.00 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a market cap of $247.91 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 1.17 and a beta of 0.39. The firm has a fifty day moving average price of $100.01 and a two-hundred day moving average price of $109.85. Merck & Co., Inc. has a fifty-two week low of $94.48 and a fifty-two week high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $16.66 billion for the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $2.13 earnings per share. Analysts expect that Merck & Co., Inc. will post 7.7 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 8th. Investors of record on Monday, December 16th were paid a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.31%. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Monday, December 16th. Merck & Co., Inc.’s dividend payout ratio is presently 67.92%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MRK. Leerink Partners reduced their price objective on Merck & Co., Inc. from $136.00 to $119.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Guggenheim lowered their price target on Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Hsbc Global Res upgraded Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 4th. Citigroup reduced their target price on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Truist Financial restated a “hold” rating and set a $110.00 price target (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $123.67.

Read Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.